In adult patients with moderate‑to‑severe traumatic brain injury and persistent disorders of consciousness or post‑traumatic cognitive impairment, what are the indications, dosing regimen, duration, and monitoring recommendations for amantadine?

Amantadine in Traumatic Brain Injury

Amantadine should be used in adult patients with moderate-to-severe TBI and persistent disorders of consciousness, initiated at 100 mg twice daily (200 mg/day) for 4 weeks, starting as early as possible after injury stabilization, with dose adjustments required for renal impairment and close monitoring for seizures and CNS side effects.

Indications

Amantadine is indicated for:

• Disorders of consciousness (vegetative state or minimally conscious state) persisting 4-16 weeks after moderate-to-severe TBI 1
• Post-traumatic cognitive impairment in the acute to subacute phase after severe TBI 2

The strongest evidence supports use in patients with persistent disorders of consciousness rather than chronic cognitive deficits. One high-quality RCT showed amantadine accelerated functional recovery during active treatment in patients 4-16 weeks post-TBI 1, while another study found no benefit—and possible early harm—in chronic TBI (>6 months) with cognitive impairment 3. Start amantadine early (within the first few weeks after injury) for maximum benefit, as meta-analysis demonstrates earlier initiation correlates with better outcomes 4.

Dosing Regimen

Standard Adult Dosing

• Initial dose: 100 mg twice daily (200 mg/day total) 5, 1
• Route: Oral or via enteral feeding tube 2
• Timing: Divided doses (morning and afternoon/evening) to minimize CNS side effects 5

Renal Impairment Adjustments (Critical)

Dose reduction is mandatory for renal dysfunction 5:

• CrCl 30-50 mL/min: 200 mg on day 1, then 100 mg daily
• CrCl 15-29 mL/min: 200 mg on day 1, then 100 mg every other day
• CrCl <15 mL/min: 200 mg every 7 days
• Hemodialysis: 200 mg every 7 days

Age-Related Adjustments

• Patients ≥65 years: Maximum 100 mg daily due to age-related decline in renal function 5
• Consider starting at 100 mg daily in elderly patients with serious comorbidities, then increase if tolerated 5

Duration of Treatment

Treat for 4 weeks based on the landmark NEJM trial 1. This duration showed:

• Accelerated functional recovery during active treatment (0.24 DRS points/week improvement, p=0.007)
• Slowed recovery rate after discontinuation (suggesting ongoing benefit during treatment)
• Similar overall improvement at 6 weeks (2 weeks post-treatment) compared to placebo

Meta-analysis suggests treatment <1 month is more effective than longer durations 4. Consider extending beyond 4 weeks only if clear ongoing benefit is observed, though evidence for prolonged use is limited.

Monitoring Recommendations

Baseline Assessment

• Renal function (creatinine clearance calculation mandatory) 5
• Baseline functional status: Disability Rating Scale (DRS), Glasgow Coma Scale (GCS), or Glasgow Outcome Scale (GOS)
• Seizure history (amantadine lowers seizure threshold)

During Treatment

• Weekly functional assessments using DRS or GCS for first 4 weeks 1
• Monitor for seizures: 8/50 patients (16%) in one study developed convulsions requiring drug discontinuation 2
• CNS side effects: nervousness, anxiety, difficulty concentrating, lightheadedness, hallucinations, delirium 5
• Observe for adverse effects in patients with any degree of renal insufficiency 5

Post-Treatment

• 2-week follow-up after discontinuation to assess sustained benefit 1
• Expect slower recovery rate after stopping (0.30 DRS points/week slower than placebo, p=0.02) 1

Critical Caveats and Pitfalls

When NOT to Use Amantadine

• Chronic TBI (>6 months): May impede cognitive processing in first 28 days with no ultimate benefit 3
• Uncontrolled seizure disorder: Amantadine lowers seizure threshold
• Severe renal impairment without dose adjustment: Risk of toxic accumulation and severe CNS effects 5

Common Pitfalls to Avoid

1. Failing to adjust for renal function: This is the most common cause of toxicity. Always calculate CrCl before prescribing 5
2. Using in chronic phase: Evidence supports early use (weeks 4-16 post-injury), not chronic cognitive deficits 1, 3
3. Ignoring seizure risk: Have antiepileptic plan ready; 16% seizure rate reported in one study 2
4. Expecting sustained benefit after discontinuation: Recovery rate slows significantly after stopping 1

Drug Interactions

Monitor closely when combining with:

• Other CNS stimulants (increased side effect risk)
• Anticholinergic drugs (additive effects)
• Medications affecting renal tubular secretion (altered clearance)

Evidence Quality Considerations

The 2012 NEJM multicenter RCT 1 provides the highest-quality evidence (184 patients, double-blind, placebo-controlled). However, the benefit was primarily in rate of recovery during treatment, not ultimate functional outcome at 6 weeks. Recent 2024 meta-analyses 6, 7 show mixed results: improved day-7 GCS and MMSE scores but no difference in DRS at weeks 3-4 or ultimate GOS. The 2023 AHA/ASA subarachnoid hemorrhage guidelines 8 note amantadine's safety and possible efficacy can be extrapolated from TBI literature, with median initiation around 19 days post-injury.

The evidence supports amantadine as a temporizing agent to accelerate early recovery in disorders of consciousness, not as a definitive treatment for chronic cognitive impairment.